129 related articles for article (PubMed ID: 23304735)
1. Pushback on Zaltrap's price highlights sensitive end-of-life issue.
Dalzell MD
Manag Care; 2012 Dec; 21(12):40-1. PubMed ID: 23304735
[No Abstract] [Full Text] [Related]
2. The development of a value based pricing index for new drugs in metastatic colorectal cancer.
Dranitsaris G; Truter I; Lubbe MS
Eur J Cancer; 2011 Jun; 47(9):1299-304. PubMed ID: 21493060
[TBL] [Abstract][Full Text] [Related]
3. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
Dranitsaris G; Ortega A; Lubbe MS; Truter I
J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
[TBL] [Abstract][Full Text] [Related]
4. The drug that could have been.
Schultz S
US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678
[No Abstract] [Full Text] [Related]
5. QOPI, the ASCO initiative, improves compliance and promotes quality of patient care.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E1. PubMed ID: 25618629
[No Abstract] [Full Text] [Related]
6. Expensive cancer therapies: unintended effects.
Delude CM
J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
[No Abstract] [Full Text] [Related]
7. Satisfying the requirements of the Food and Drug Administration and Centers for Medicare and Medicare Services.
Smith JJ; Henderson JA
J Am Coll Radiol; 2008 Mar; 5(3):189-92. PubMed ID: 18312966
[TBL] [Abstract][Full Text] [Related]
8. Valuing end-of-life care in the United States: the case of new cancer drugs.
Sorenson C
Health Econ Policy Law; 2012 Oct; 7(4):411-30. PubMed ID: 23079300
[TBL] [Abstract][Full Text] [Related]
9. Use and coverage of novel cancer agents in managed care.
Bailes JS
Semin Oncol; 1994 Dec; 21(6 Suppl 14):34-7. PubMed ID: 7992098
[TBL] [Abstract][Full Text] [Related]
10. The value of new chemotherapeutic agents for metastatic colorectal cancer.
Howard DH; Kauh J; Lipscomb J
Arch Intern Med; 2010 Mar; 170(6):537-42. PubMed ID: 20233802
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer: complexities and challenges in managed care.
Minkoff NB
J Manag Care Pharm; 2007 Aug; 13(6 Suppl C):S27-9. PubMed ID: 17713992
[TBL] [Abstract][Full Text] [Related]
12. Market watch: Upcoming catalysts in Q1 2015.
Uribe A
Nat Rev Drug Discov; 2015 Jan; 14(1):9. PubMed ID: 25503330
[No Abstract] [Full Text] [Related]
13. New drug approved for colorectal cancer.
FDA Consum; 2002; 36(5):2. PubMed ID: 12412532
[No Abstract] [Full Text] [Related]
14. Genentech caps cost of cancer drug for some patients.
Pollack A
N Y Times Web; 2006 Oct; ():C2. PubMed ID: 17061339
[No Abstract] [Full Text] [Related]
15. FDA approves regorafenib (Stivarga) for metastatic colorectal cancer.
Oncology (Williston Park); 2012 Oct; 26(10):896. PubMed ID: 23175993
[No Abstract] [Full Text] [Related]
16. Time for a level playing field: inequalities in regulatory/approval processes—the example of bevacizumab in epithelial ovarian cancer.
Hoskins PJ; Fung-Kee-Fung M; Miller D; Gotlieb W
J Clin Oncol; 2015 May; 33(14):1539-42. PubMed ID: 25847922
[No Abstract] [Full Text] [Related]
17. Current and future state of FDA-CMS parallel reviews.
Messner DA; Tunis SR
Clin Pharmacol Ther; 2012 Mar; 91(3):383-5. PubMed ID: 22343814
[TBL] [Abstract][Full Text] [Related]
18. Cost of Cancer Drugs: Something Has To Give.
Bender E
Manag Care; 2018 May; 27(5):18-22. PubMed ID: 29763403
[TBL] [Abstract][Full Text] [Related]
19. Stocks' study renews concerns over insider trading on oncology drugs.
Goozner M
J Natl Cancer Inst; 2011 Nov; 103(22):1652-5. PubMed ID: 22025626
[No Abstract] [Full Text] [Related]
20. When will the U.S. flinch at cancer drug prices?
Vanchieri C
J Natl Cancer Inst; 2005 May; 97(9):624-6. PubMed ID: 15870428
[No Abstract] [Full Text] [Related]
[Next] [New Search]
